Combination of therapeutic hypothermia and other neuroprotective strategies after an ischemic cerebral insult

Current Neuropharmacology

Volumn 12, Issue 5, 2014, Pages 399-412

  Goossens, Joline ^a   Hachimi Idrissi, Saïd ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Acute ischemic stroke; Clinical; Combination therapy; Experimental; Human; Hypothermia; Neuroprotection; Rodent

Indexed keywords

ALBUMIN; ALCOHOL; ALTEPLASE; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ARGATROBAN; ATORVASTATIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CAFFEINE; CITICOLINE; DEXTROMETHORPHAN; DIZOCILPINE; KETOPROFEN; MAGNESIUM; MAGNESIUM SULFATE; MANNITOL; METHOHEXITAL; MINOCYCLINE; N ACETYLASPARTYLGLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NORPHENAZONE; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; STATIN (PROTEIN); TACROLIMUS; TIRILAZAD; XENON;

ARTICLE; BARTHEL INDEX; BRAIN DAMAGE; BRAIN ISCHEMIA; CALCIUM TRANSPORT; CELL FUNCTION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); CRANIECTOMY; DRUG EFFICACY; DRUG SAFETY; GENE THERAPY; HEMICRANIECTOMY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INDUCED HYPOTHERMIA; MOLECULAR THERAPY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; SCIENTIST; SIDE EFFECT;

EID: 84924122415     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X12666140424233036     Document Type: Article

References (192)

1. Goldstein, L. B. Acute ischemic stroke treatment in 2007. Circulation, 2007, 116(13), 1504-1514. DOI: http://dx.doi.org/10. 1161/CIRCULATIONAHA.106.670885
2. Hacke, W.; Kaste, M.; Bluhmki, E.; Brozman, M.; Davalos, A.; Guidetti, D.; Larrue, V.; Lees, K. R.; Medeghri, Z.; Machnig, T.; Schneider, D.; von Kummer, R.; Wahlgren, N.; Toni, D.; Investigators, E. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med., 2008, 359(13), 1317-1329. DOI: http://dx.doi.org/10.1056/NEJMoa0804656
3. Lees, K. R.; Bluhmki, E.; von Kummer, R.; Brott, T. G.; Toni, D.; Grotta, J. C.; Albers, G. W.; Kaste, M.; Marler, J. R.; Hamilton, S. A.; Tilley, B. C.; Davis, S. M.; Donnan, G. A.; Hacke, W.; Ecass, A. N.; Group, E. r.-P. S.; Allen, K.; Mau, J.; Meier, D.; del Zoppo, G.; De Silva, D. A.; Butcher, K. S.; Parsons, M. W.; Barber, P. A.; Levi, C.; Bladin, C.; Byrnes, G. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet, 2010, 375(9727), 1695-1703. DOI: http://dx.doi.org/10.1016/S0140- 6736(10)60491-6
4. Hacke, W.; Kaste, M.; Fieschi, C.; Toni, D.; Lesaffre, E.; von Kummer, R.; Boysen, G.; Bluhmki, E.; Hoxter, G.; Mahagne, M. H.; Hennerici, M. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA, 1995, 274(13), 1017-1025. DOI: http://dx.doi.org/10.1001/jama.274.13.1017
5. Ginsberg, M. D. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology, 2008, 55(3), 363-389. DOI: http://dx.doi.org/10.1016/j.neuropharm.2007.12.007
6. Brouns, R.; De Deyn, P. P. The complexity of neurobiological processes in acute ischemic stroke. Clin. Neurol. Neurosurg., 2009, 111(6), 483-495. DOI: http://dx.doi.org/10.1016/j.clineuro.2009.04.001
7. Doyle, K. P.; Simon, R. P.; Stenzel-Poore, M. P. Mechanisms of ischemic brain damage. Neuropharmacology, 2008, 55(3), 310-318. DOI: http://dx.doi.org/10.1016/j.neuropharm.2008.01.005
8. Durukan, A.; Tatlisumak, T. Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol. Biochem. Behav., 2007, 87(1), 179-197. DOI: http://dx.doi.org/10.1016/j.pbb.2007.04.015
9. Dirnagl, U.; Iadecola, C.; Moskowitz, M. A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci., 1999, 22(9), 391-397. DOI: http://dx.doi.org/10.1016/S0166-2236(99)01401-0
10. Hossmann, K. A. Pathophysiology and therapy of experimental stroke. Cell. Mol. Neurobiol., 2006, 26(7-8), 1057-1083. DOI: http://dx.doi.org/10.1016/j.nbd.2010.03.001
11. Lyden, P. D.; Krieger, D.; Yenari, M.; Dietrich, W. D. Therapeutic hypothermia for acute stroke. Int. J. Stroke, 2006, 1(1), 9-19. DOI: http://dx.doi.org/10.1111/j.1747-4949.2005.00011.x
12. So, H. Y. Therapeutic hypothermia. Korean J. Anesthesiol., 2010, 59(5), 299-304. DOI: http://dx.doi.org/10.4097/kjae.2010.59.5.299
13. Gupta, R.; Jovin, T. G.; Krieger, D. W. Therapeutic hypothermia for stroke: do new outfits change an old friend? Expert Rev. Neurother., 2005, 5(2), 235-246. DOI: http://dx.doi.org/10.1586/14737175.5.2.235
14. Lanier, W. L. Cerebral Metabolic-Rate and Hypothermia - Their Relationship with Ischemic Neurologic Injury. J. Neurosurg. Anesthesiol., 1995, 7(3), 216-221. DOI: http://dx.doi.org/10.1097/ 00008506-199507000-00021
15. Busto, R.; Globus, M. Y.; Dietrich, W. D.; Martinez, E.; Valdes, I.; Ginsberg, M. D. Effect of mild hypothermia on ischemia-induced release of neurotransmitters and free fatty acids in rat brain. Stroke, 1989, 20(7), 904-910. DOI: http://dx.doi.org/10.1161/01.STR.20. 7.904
16. Busto, R.; Globus, M. Y.; Dietrich, W. D.; Martinez, E.; Valdes, I.; Ginsberg, M. D. Effect of Mild Hypothermia on Ischemia-Induced Release of Neurotransmitters and Free Fatty-Acids in Rat-Brain. Stroke, 1989, 20(7), 904-910. DOI: http://dx.doi.org/10.1161/ 01.STR.20.7.904
17. Globus, M. Y.; Alonso, O.; Dietrich, W. D.; Busto, R.; Ginsberg, M. D. Glutamate release and free radical production following brain injury: effects of posttraumatic hypothermia. J. Neurochem., 1995, 65(4), 1704-1711. DOI: http://dx.doi.org/10.1046/j.1471-4159. 1995.65041704.x
18. Deng, H.; Han, H. S.; Cheng, D.; Sun, G. H.; Yenari, M. A. Mild hypothermia inhibits inflammation after experimental stroke and brain inflammation. Stroke, 2003, 34(10), 2495-2501. DOI: http:// dx.doi.org/10.1161/01.STR.0000091269.67384.E7
19. Smith, S. L.; Hall, E. D. Mild pre- and posttraumatic hypothermia attenuates blood-brain barrier damage following controlled cortical impact injury in the rat. J. Neurotrauma, 1996, 13(1), 1-9. DOI: http://dx.doi.org/10.1089/neu.1996.13.1
20. Liu, L. P.; Yenari, M. A. Clinical application of therapeutic hypothermia in stroke. Neurol. Res., 2009, 31(4), 331-335. DOI: http://dx.doi.org/10.1179/174313209X444099
21. Krieger, D. W.; Yenari, M. A. Therapeutic hypothermia for acute ischemic stroke - What do laboratory studies teach us? Stroke, 2004, 35(6), 1482-1489. DOI: http://dx.doi.org/10.1161/01.STR. 0000126118.44249.5c
22. Zhao, H.; Steinberg, G. K.; Sapolsky, R. M. General versus specific actions of mild-moderate hypothermia in attenuating cerebral ischemic damage. J. Cereb. Blood Flow Metab., 2007, 27(12), 1879-1894. DOI: http://dx.doi.org/10.1038/sj.jcbfm.9600540
23. Zgavc, T.; Ceulemans, A. G.; Sarre, S.; Michotte, Y.; Hachimi- Idrissi, S. Experimental and clinical use of therapeutic hypothermia for ischemic stroke: opportunities and limitations. Stroke Res. Treat., 2011, 2011, 689290.
24. Tang, X. N.; Liu, L.; Yenari, M. A. Combination therapy with hypothermia for treatment of cerebral ischemia. J. Neurotrauma, 2009, 26(3), 325-331. DOI: http://dx.doi.org/10.4061/2011/689290
25. Hemmen, T. M.; Lyden, P. D. Multimodal neuroprotective therapy with induced hypothermia after ischemic stroke. Stroke, 2009, 40(3 Suppl), S126-128. DOI: http://dx.doi.org/10.1161/STROKEAHA. 108.533083
26. Zeiner, A.; Holzer, M.; Sterz, F.; Behringer, W.; Schorkhuber, W.; Mullner, M.; Frass, M.; Siostrzonek, P.; Ratheiser, K.; Kaff, A.; Laggner, A. N. Mild resuscitative hypothermia to improve neurological outcome after cardiac arrest. A clinical feasibility trial. Hypothermia After Cardiac Arrest (HACA) Study Group. Stroke, 2000, 31(1), 86-94.
27. Choi, D. W. Glutamate neurotoxicity and diseases of the nervous system. Neuron, 1988, 1(8), 623-634. DOI: http://dx.doi.org/10. 1016/0896-6273(88)90162-6
28. Meldrum, B. Protection against ischaemic neuronal damage by drugs acting on excitatory neurotransmission. Cerebrovasc. Brain Metab. Rev., 1990, 2(1), 27-57. PMID: 2169834
29. Mitani, A.; Kataoka, K. Critical levels of extracellular glutamate mediating gerbil hippocampal delayed neuronal death during hypothermia: brain microdialysis study. Neuroscience, 1991, 42(3), 661-670. DOI: http://dx.doi.org/10.1016/0306-4522(91)90035-M
30. Ginsberg, M. D.; Globus, M. Y. T.; Busto, R.; Dietrich, W. D. The Potential of Combination Pharmacotherapy in Cerebral- Ischemia. In: Krieglstein, J.; Oberpichler, H, Eds. Pharmacology Cerebral Ischemia, 1990, Stuttgart, Germany: Wissenschaftliche Verlagsgesellschaft, mbh; 1990, 499-510.
31. Frazzini, V. I.; Winfree, C. J.; Choudhri, H. F.; Prestigiacomo, C. J.; Solomon, R. A. Mild Hypothermia and Mk-801 Have Similar but Not Additive Degrees of Cerebroprotection in the Rat Permanent Focal Ischemia Model. Neurosurgery, 1994, 34(6), 1040-1045. DOI:10.1227/00006123-199406000-00013
32. Meloni, B. P.; Zhu, H.; Knuckey, N. W. Is magnesium neuroprotective following global and focal cerebral ischaemia? A review of published studies. Magnes. Res., 2006, 19(2), 123-137. PMID: 16955724
33. Nowak, L.; Bregestovski, P.; Ascher, P.; Herbet, A.; Prochiantz, A. Magnesium gates glutamate-activated channels in mouse central neurones. Nature, 1984, 307(5950), 462-465. DOI: http://dx.doi. org/10.1038/307462a0
34. Campbell, K.; Meloni, B. P.; Knuckey, N. W. Combined magnesium and mild hypothermia (35 degrees C) treatment reduces infarct volumes after permanent middle cerebral artery occlusion in the rat at 2 and 4, but not 6 h. Brain Res., 2008, 1230, 258-264. DOI: http://dx.doi.org/10.1016/j.brainres.2008.06.110
35. Song, W.; Wu, Y. M.; Ji, Z.; Ji, Y. B.; Wang, S. N.; Pan, S. Y. Intra-carotid cold magnesium sulfate infusion induces selective cerebral hypothermia and neuroprotection in rats with transient middle cerebral artery occlusion. Neurol. Sci., 2013, 34(4), 479-486. DOI: http://dx.doi.org/10.1007/s10072-012-1064-3
36. Meloni, B. P.; Cross, J. L.; Brookes, L. M.; Clark, V. W.; Campbell, K.; Knuckey, N. W. FAST-Mag protocol with or without mild hypothermia (35 degrees C) does not improve outcome after permanent MCAO in rats. Magnes. Res., 2013, 26(2), 67-73. DOI: http://dx.doi.org/10.1097/SHK.0b013e3181e86f49
37. Coyle, J. T. The nagging question of the function of Nacetylaspartylglutamate. Neurobiol. Dis., 1997, 4(3-4), 231-238. DOI: http://dx.doi.org/10.1006/nbdi.1997.0153
38. Neale, J. H.; Bzdega, T.; Wroblewska, B. N-acetylaspartylglutamate: The most abundant peptide neurotransmitter in the mammalian central nervous system. J. Neurochem., 2000, 75(2), 443-452. DOI: http://dx.doi.org/10.1046/j.1471-4159.2000.0750443.x
39. Cai, Z. W.; Lin, S. Y.; Rhodes, P. G. Neuroprotective effects of Nacetylaspartylglutamate in a neonatal rat model of hypoxiaischemia. Eur. J. Pharmacol., 2002, 437(3), 139-145. DOI: http:// dx.doi.org/10.1016/S0014-2999(02)01289-X
40. Pin, J. P.; Duvoisin, R. The Metabotropic Glutamate Receptors - Structure and Functions. Neuropharmacology, 1995, 34(1), 1-26. PMID: 7623957
41. Van Hemelrijck, A.; Hachimi-Idrissi, S.; Sarre, S.; Ebinger, G.; Michotte, Y. Neuroprotective effect of N-acetyl-aspartyl-glutamate in combination with mild hypothermia in the endothelin-1 rat model of focal cerebral ischaemia. J. Neurochem., 2005, 95(5), 1287- 1297. DOI: http://dx.doi.org/10.1111/j.1471-4159.2005.03450.x
42. Dingledine, R.; Borges, K.; Bowie, D.; Traynelis, S. F. The glutamate receptor ion channels. Pharmacol. Rev., 1999, 51(1), 7-61. PMID: 10049997
43. Haberny, K. A.; Paule, M. G.; Scallet, A. C.; Sistare, F. D.; Lester, D. S.; Hanig, J. P.; Slikker, W., Jr. Ontogeny of the N-methyl-Daspartate (NMDA) receptor system and susceptibility to neurotoxicity. Toxicol. Sci., 2002, 68(1), 9-17. DOI: http://dx.doi. org/10.1093/toxsci/68.1.9
44. Hardingham, G. E.; Bading, H. The Yin and Yang of NMDA receptor signalling. Trends Neurosci., 2003, 26(2), 81-89. DOI: http://dx.doi.org/10.1016/S0166-2236(02)00040-1
45. Ikonomidou, C.; Bosch, F.; Miksa, M.; Bittigau, P.; Vockler, J.; Dikranian, K.; Tenkova, T. I.; Stefovska, V.; Turski, L.; Olney, J. W. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science, 1999, 283(5398), 70-74. DOI: http://dx.doi.org/10.1126/science.283.5398.70
46. Gladstone, D. J.; Black, S. E.; Hakim, A. M. Heart Stroke Foundation of Ontario Centre of Excellence in Stroke, R. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke, 2002, 33(8), 2123-2136. DOI: http://dx.doi.org/10.1161/01.STR.0000025518.34157.51
47. Ikonomidou, C.T. L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol., 2002, 1(6), 383-386. DOI: http://dx.doi.org/10.1016/S1474-4422 (02)00164-3
48. Chan, P. H. Role of oxidants in ischemic brain damage. Stroke, 1996, 27(6), 1124-1129. DOI: http://dx.doi.org/10.1161/01.STR. 27.6.1124
49. Ji, X.; Luo, Y.; Ling, F.; Stetler, R. A.; Lan, J.; Cao, G.; Chen, J. Mild hypothermia diminishes oxidative DNA damage and prodeath signaling events after cerebral ischemia: a mechanism for neuroprotection. Front Biosci., 2007, 12, 1737-1747. DOI: http://dx.doi.org/10.2741/2185
50. Nito, C.; Kamiya, T.; Amemiya, S.; Katoh, K.; Katayama, Y. The neuroprotective effect of a free radical scavenger and mild hypothermia following transient focal ischemia in rats. Acta Neurochir. Suppl., 2003, 86, 199-203. DOI: http://dx.doi.org/10. 1007/978-3-7091-0651-8_43
51. Eddleston, M.; de la Torre, J. C.; Oldstone, M. B.; Loskutoff, D. J.; Edgington, T. S.; Mackman, N. Astrocytes are the primary source of tissue factor in the murine central nervous system. A role for astrocytes in cerebral hemostasis. J. Clin. Invest., 1993, 92(1), 349- 358. DOI: http://dx.doi.org/10.1172/JCI116573
52. Grotta, J.; Marler, J. Intravenous rt-PA: a tenth anniversary reflection. Surgical Neurol., 2007, 68 (1), 12-16. DOI: http://dx. doi.org/10.1016/j.surneu.2007.07.079
53. Liu, L. P.; Tang, X. N.; Yenari, M. A. Mild hypothermia reduces hemorrhage and blood brain barrier (BBB) disruption following tissue plasminogen activator treatment in experimental stroke. Neurology, 2006, 66(5), A242-A243. ISSN: 0028-3878, IDS Number: 022PM, Accession Number: WOS:000236068103009
54. Kallmunzer, B.; Schwab, S.; Kollmar, R. Mild hypothermia of 34 degrees C reduces side effects of rt-PA treatment after thromboembolic stroke in rats. Exp. Transl. Stroke Med., 2012, 4(1), 3. DOI: http://dx.doi.org/10.1186/2040-7378-4-3
55. Meden, P.; Overgaard, K.; Pedersen, H.; Boysen, G. Effect of hypothermia and delayed thrombolysis in a rat embolic stroke model. Acta Neurol. Scand., 1994, 90(2), 91-98. DOI: http://dx.doi.org/10.1111/j.1600-0404.1994.tb02686.x
56. Kollmar, R.; Henninger, N.; Bardutzky, J.; Schellinger, P. D.; Schabitz, W. R.; Schwab, S. Combination therapy of moderate hypothermia and thrombolysis in experimental thromboembolic stroke--an MRI study. Exp. Neurol., 2004, 190(1), 204-212. DOI: http://dx.doi.org/10.1111/j.1600-0404.1994.tb02686.x
57. Bi, M.; Ma, Q.; Zhang, S.; Li, J.; Zhang, Y.; Lin, L.; Tong, S.; Wang, D. Local mild hypothermia with thrombolysis for acute ischemic stroke within a 6-h window. Clin. Neurol. Neurosurg., 2011, 113(9), 768-773. DOI: http://dx.doi.org/10.1016/j.clineuro. 2011.08.010
58. Hemmen, T. M.; Raman, R.; Guluma, K. Z.; Meyer, B. C.; Gomes, J. A.; Cruz-Flores, S.; Wijman, C. A.; Rapp, K. S.; Grotta, J. C.; Lyden, P. D.; Investigators, I. C.-L. Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L): final results. Stroke, 2010, 41(10), 2265-2270. DOI: http://dx.doi. org/10.1161/STROKEAHA.110.592295
59. Okamoto, S.; Hijikata-Okunomiya, A. Synthetic selective inhibitors of thrombin. Methods Enzymol., 1993, 222, 328-340. DOI: http://dx.doi.org/10.1016/0076-6879(93)22022-8
60. Swan, S. K.; Hursting, M. J. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy, 2000, 20(3), 318-329. DOI: http://dx.doi.org/10.1592/phco.20.4.318.34881
61. Berry, C. N.; Girard, D.; Lochot, S.; Lecoffre, C. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time. Br. J. Pharmacol., 1994, 113(4), 1209-1214. DOI: http://dx.doi.org/ 10.1111/j.1476-5381.1994.tb17126.x
62. Kathiresan, S.; Shiomura, J.; Jang, I. K. Argatroban. J. Thromb. Thrombolysis, 2002, 13(1), 41-47. PMID: 11994559
63. Kawai, H.; Yuki, S.; Sugimoto, J.; Tamao, Y. Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J. Pharmacol. Exp. Ther., 1996, 278(2), 780-785. PMID: 8768731
64. Morris, D. C.; Zhang, L.; Zhang, Z. G.; Lu, M.; Berens, K. L.; Brown, P. M.; Chopp, M. Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke. Stroke, 2001, 32(11), 2635-2640. DOI: http://dx.doi.org/10.1161/hs1101.097390
65. Kamiya, T.; Nito, C.; Ueda, M.; Kato, K.; Amemiya, S.; Terashi, A.; Katayama, Y. Mild hypothermia enhances the neuroprotective effects of a selective thrombin inhibitor following transient focal ischemia in rats. Acta Neurochir. Suppl., 2003, 86, 195-198. DOI: http://dx.doi.org/10.1007/978-3-7091-0651-8_42
66. Laufs, U.; La Fata, V.; Plutzky, J.; Liao, J. K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation, 1998, 97(12), 1129-1135. DOI: http://dx. doi.org/10.1161/01.CIR.97.12.1129
67. Laufs, U.; Gertz, K.; Huang, P.; Nickenig, G.; Bohm, M.; Dirnagl, U.; Endres, M. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke, 2000, 31(10), 2442-2449. DOI: http://dx.doi.org/10.1161/ 01.STR.31.10.2442
68. Endres, M.; Laufs, U.; Huang, Z.; Nakamura, T.; Huang, P.; Moskowitz, M. A.; Liao, J. K. Stroke protection by 3-hydroxy-3- methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A., 1998, 95(15), 8880-8885. PMID: 9671773
69. Lee, S. H.; Kim, Y. H.; Kim, Y. J.; Yoon, B. W. Atorvastatin enhances hypothermia-induced neuroprotection after stroke. J. Neurol. Sci., 2008, 275(1-2), 64-68. DOI: http://dx.doi.org/10. 1016/j.jns.2008.07.029
70. Giulian, D. Reactive Glia as Rivals in Regulating Neuronal Survival. Glia, 1993, 7(1), 102-110. DOI: http://dx.doi.org/10. 1002/glia.440070116
71. Giulian, D. Ameboid Microglia as Effectors of Inflammation in the Central-Nervous-System. J. Neurosci. Res., 1987, 18(1), 155-171. DOI: http://dx.doi.org/10.1002/jnr.490180123
72. Feuerstein, G. Z.; Liu, T.; Barone, F. C. Cytokines, inflammation, and brain injury: role of tumor necrosis factor-alpha. Cerebrovasc. Brain Metab. Rev., 1994, 6(4), 341-360. PMID: 7880718
73. Becker, K. J. Inflammation and acute stroke. Curr. Opin. Neurol., 1998, 11(1), 45-49. DOI: http://dx.doi.org/10.1097/00019052- 199802000-00008
74. Furuichi, Y.; Katsuta, K.; Maeda, M.; Ueyama, N.; Moriguchi, A.; Matsuoka, N.; Goto, T.; Yanagihara, T. Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: dose dependency, therapeutic time window and long-term efficacy. Brain Res., 2003, 965(1-2), 137-145. DOI: http://dx.doi.org/10.1016/S0006-8993(02)04151-3
75. Ide, T.; Morikawa, E.; Kirino, T. An immunosuppressant, FK506, protects hippocampal neurons from forebrain ischemia in the mongolian gerbil. Neurosci. Lett., 1996, 204(3), 157-160. DOI: http://dx.doi.org/10.1016/0304-3940(96)12352-1
76. Wakita, H.; Tomimoto, H.; Akiguchi, I.; Kimura, J. Dosedependent, protective effect of FK506 against white matter changes in the rat brain after chronic cerebral ischemia. Brain Res., 1998, 792(1), 105-113. DOI: http://dx.doi.org/10.1016/S0006-8993(98) 00126-7
77. Nito, C.; Kamiya, T.; Ueda, M.; Arii, T.; Katayama, Y. Mild hypothermia enhances the neuroprotective effects of FK506 and expands its therapeutic window following transient focal ischemia in rats. Brain Res., 2004, 1008(2), 179-185. DOI: http://dx.doi.org/ 10.1016/j.brainres.2004.02.031
78. Tirapelli, D. P. D.; Carlotti, C. G.; Leite, J. P.; Tirapelli, L. F.; Colli, B. O. Expression of HSP70 in cerebral ischemia and neuroprotetive action of hypothermia and ketoprofen. Arq. Neuropsiquiatr., 2010, 68(4), 592-596. DOI: http://dx.doi.org/10.1590/S0004-282 X2010000400021
79. Kennedy, E. P. The synthesis of cytidine diphosphate choline, cytidine diphosphate ethanolamine, and related compounds. J. Biol. Chem., 1956, 222(1), 185-191. PMID: 13366992
80. Adibhatla, R. M.; Hatcher, J. F. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J. Neurosci. Res., 2002, 70(2), 133-139. DOI: http://dx.doi.org/10.1002/jnr.10403
81. Trovarelli, G.; Demedio, G. E.; Dorman, R. V.; Piccinin, G. L.; Horrocks, L. A.; Porcellati, G. Effect of Cytidine Diphosphate Choline (Cdp-Choline) on Ischemia-Induced Alterations of Brain Lipid in the Gerbil. Neurochem. Res., 1981, 6(8), 821-833. DOI: http://dx.doi.org/10.1007/BF00965041
82. Rao, A. M.; Hatcher, J. F.; Dempsey, R. J. Lipid alterations in transient forebrain ischemia: possible new mechanisms of CDPcholine neuroprotection. J. Neurochem., 2000, 75(6), 2528-2535. DOI: http://dx.doi.org/10.1046/j.1471-4159.2000.0752528.x
83. Schabitz, W. R.; Li, F.; Irie, K.; Sandage, B. W., Jr.; Locke, K. W.; Fisher, M. Synergistic effects of a combination of low-dose basic fibroblast growth factor and citicoline after temporary experimental focal ischemia. Stroke, 1999, 30(2), 427-431; discussion 431-422. DOI: http://dx.doi.org/10.1161/01.STR.30.2.427
84. Weiss, G. B. Metabolism and Actions of Cdp-Choline as an Endogenous Compound and Administered Exogenously as Citicoline. Life Sci., 1995, 56(9), 637-660. DOI: http://dx.doi.org/ 10.1016/0024-3205(94)00427-T
85. Krupinski, J.; Ferrer, I.; Barrachina, M.; Secades, J. J.; Mercadal, J.; Lozano, R. CDP-choline reduces pro-caspase and cleaved caspase-3 expression, nuclear DNA fragmentation, and specific PARP-cleaved products of caspase activation following middle cerebral artery occlusion in the rat. Neuropharmacology, 2002, 42(6), 846-854. DOI: http://dx.doi.org/10.1016/S0028-3908(02) 00032-1
86. Sahin, S.; Alkan, T.; Temel, S. G.; Tureyen, K.; Tolunay, S.; Korfali, E. Effects of citicoline used alone and in combination with mild hypothermia on apoptosis induced by focal cerebral ischemia in rats. J. Clin. Neurosci., 2010, 17(2), 227-231. DOI: http://dx.doi.org/10.1016/j.jocn.2009.05.016
87. Macdonald, H.; Kelly, R. G.; Allen, E. S.; Noble, J. F.; Kanegis, L. A. Pharmacokinetic studies on minocycline in man. Clin. Pharmacol. Ther., 1973, 14(5), 852-861. DOI: http://dx.doi.org/ 10.1136/jmg.38.12.852
88. Tikka, T.; Fiebich, B. L.; Goldsteins, G.; Keinanen, R.; Koistinaho, J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J. Neurosci., 2001, 21(8), 2580-2588. PMID: 11306611
89. Yrjanheikki, J.; Keinanen, R.; Pellikka, M.; Hokfelt, T.; Koistinaho, J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl. Acad. Sci. U. S. A., 1998, 95(26), 15769-15774. DOI: http://dx.doi.org/10.1073/ pnas.95.26.15769
90. Scarabelli, T. M.; Stephanou, A.; Pasini, E.; Gitti, G.; Townsend, P.; Lawrence, K.; Chen-Scarabelli, C.; Saravolatz, L.; Latchman, D.; Knight, R.; Gardin, J. Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO. J. Am. Coll. Cardiol., 2004, 43(5), 865-874. f DOI: http://dx.doi.org/10.1016/j.jacc.2003.09.050
91. Morimoto, N.; Shimazawa, M.; Yamashima, T.; Nagai, H.; Hara, H. Minocycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damage. Brain Res., 2005, 1044(1), 8-15. DOI: http://dx.doi.org/10.1016/j.brainres.2005.02.062
92. Yrjanheikki, J.; Tikka, T.; Keinanen, R.; Goldsteins, G.; Chan, P. H.; Koistinaho, J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. U S A, 1999, 96(23), 13496-13500. DOI: http://dx.doi.org/10.1073/pnas.96. 23.13496
93. Yong, V. W.; Wells, J.; Giuliani, F.; Casha, S.; Power, C.; Metz, L. M. The promise of minocycline in neurology. Lancet Neurol., 2004, 3(12), 744-751. DOI: http://dx.doi.org/10.1016/S1474- 4422(04)00937-8
94. Wang, C. X.; Yang, T.; Noor, R.; Shuaib, A. Delayed minocycline but not delayed mild hypothermia protects against embolic stroke. BMC Neurol., 2002, 2, 2. doi:10.1186/1471-2377-2-2
95. Wang, C. X.; Yang, T.; Shuaib, A. Effects of minocycline alone and in combination with mild hypothermia in embolic stroke. Brain Res., 2003, 963(1-2), 327-329. DOI: http://dx.doi.org/10.1016/ S0006-8993(02)04045-3
96. Nagel, S.; Su, Y.; Horstmann, S.; Heiland, S.; Gardner, H.; Koziol, J.; Martinez-Torres, F. J.; Wagner, S. Minocycline and hypothermia for reperfusion injury after focal cerebral ischemia in the rat: effects on BBB breakdown and MMP expression in the acute and subacute phase. Brain Res., 2008, 1188, 198-206. DOI: http://dx.doi.org/10.1016/j.brainres.2007.10.052
97. Rudolphi, K. A.; Keil, M.; Fastbom, J.; Fredholm, B. B. Ischaemic damage in gerbil hippocampus is reduced following upregulation of adenosine (A1) receptors by caffeine treatment. Neurosci. Lett., 1989, 103(3), 275-280. DOI: http://dx.doi.org/10.1016/0304- 3940(89)90112-2
98. Miller, L. P.; Hsu, C. Therapeutic potential for adenosine receptor activation in ischemic brain injury. J. Neurotrauma, 1992, 9 Suppl 2, S563-577. PMID: 1613814
99. Lovinger, D. M.; White, G.; Weight, F. F. Ethanol inhibits NMDAactivated ion current in hippocampal neurons. Science, 1989, 243(4899), 1721-1724. DOI: http://dx.doi.org/10.1126/science. 2467382
100. Phillis, J. W.; Estevez, A. Y.; O'Regan, M. H. Protective effects of the free radical scavengers, dimethyl sulfoxide and ethanol, in cerebral ischemia in gerbils. Neurosci. Lett., 1998, 244(2), 109- 111. DOI: http://dx.doi.org/10.1016/S0304-3940(98)00139-6
101. Aronowski, J.; Strong, R.; Shirzadi, A.; Grotta, J. C. Ethanol plus caffeine (caffeinol) for treatment of ischemic stroke: preclinical experience. Stroke, 2003, 34(5), 1246-1251. DOI: http://dx.doi. org/10.1161/01.STR.0000068170.80517.B3
102. Johansson, B.; Georgiev, V.; Lindstrom, K.; Fredholm, B. B. A(1) and A(2A) adenosine receptors and A(1) mRNA in mouse brain: effect of long-term caffeine treatment. Brain Res., 1997, 762(1-2), 153-164. DOI: http://dx.doi.org/10.1016/S0006-8993(97)00378-8
103. Snell, L. D.; Tabakoff, B.; Hoffman, P. L. Radioligand binding to the N-methyl-D-aspartate receptor/ionophore complex: alterations by ethanol in vitro and by chronic in vivo ethanol ingestion. Brain Res., 1993, 602(1), 91-98. DOI: http://dx.doi.org/10.1016/0006- 8993(93)90246-J
104. Chandler, L. J.; Sumners, C.; Crews, F. T. Ethanol inhibits NMDA receptor-mediated excitotoxicity in rat primary neuronal cultures. Alcohol Clin. Exp. Res., 1993, 17(1), 54-60. DOI: http://dx.doi.org/ 10.1111/j.1530-0277.1993.tb00726.x
105. Strong, R.; Grotta, J. C.; Aronowski, J. Combination of low dose ethanol and caffeine protects brain from damage produced by focal ischemia in rats. Neuropharmacology, 2000, 39(3), 515-522. DOI: http://dx.doi.org/10.1016/S0028-3908(99)00156-2
106. Martin-Schild, S.; Hallevi, H.; Shaltoni, H.; Barreto, A. D.; Gonzales, N. R.; Aronowski, J.; Savitz, S. I.; Grotta, J. C. Combined neuroprotective modalities coupled with thrombolysis in acute ischemic stroke: a pilot study of caffeinol and mild hypothermia. J. Stroke Cerebrovasc. Dis., 2009, 18(2), 86-96. DOI: http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2008.09.015
107. Dingley, J.; Tooley, J.; Porter, H.; Thoresen, M. Xenon provides short-term neuroprotection in neonatal rats when administered after hypoxia-ischemia. Stroke, 2006, 37(2), 501-506. DOI: http://dx.doi.org/10.1161/01.STR.0000198867.31134.ac
108. Luo, Y.; Ma, D.; Ieong, E.; Sanders, R. D.; Yu, B.; Hossain, M.; Maze, M. Xenon and sevoflurane protect against brain injury in a neonatal asphyxia model. Anesthesiology, 2008, 109(5), 782-789. DOI: http://dx.doi.org/10.1097/ALN.0b013e3181895f88
109. Homi, H. M.; Yokoo, N.; Ma, D.; Warner, D. S.; Franks, N. P.; Maze, M.; Grocott, H. P. The neuroprotective effect of xenon administration during transient middle cerebral artery occlusion in mice. Anesthesiology, 2003, 99(4), 876-881. DOI: http://dx.doi.org/10.1097/00000542-200310000-00020
110. David, H. N.; Leveille, F.; Chazalviel, L.; MacKenzie, E. T.; Buisson, A.; Lemaire, M.; Abraini, J. H. Reduction of ischemic brain damage by nitrous oxide and xenon. J. Cereb. Blood Flow Metab., 2003, 23(10), 1168-1173. DOI: http://dx.doi.org/10.1097/ 01.WCB.0000087342.31689.18
111. Limatola, V.; Ward, P.; Cattano, D.; Gu, J.; Giunta, F.; Maze, M.; Ma, D. Xenon preconditioning confers neuroprotection regardless of gender in a mouse model of transient middle cerebral artery occlusion. Neuroscience, 2010, 165(3), 874-881. DOI: http://dx. doi.org/10.1016/j.neuroscience.2009.10.063
112. Ma, D.; Yang, H.; Lynch, J.; Franks, N. P.; Maze, M.; Grocott, H. P. Xenon attenuates cardiopulmonary bypass-induced neurologic and neurocognitive dysfunction in the rat. Anesthesiology, 2003, 98(3), 690-698. DOI: http://dx.doi.org/10.1097/00000542-200303000- 00017
113. Schmidt, M.; Marx, T.; Gloggl, E.; Reinelt, H.; Schirmer, U. Xenon attenuates cerebral damage after ischemia in pigs. Anesthesiology, 2005, 102(5), 929-936. DOI: http://dx.doi.org/10.1097/00000542- 200505000-00011
114. Yamada, K.; Ji, J. J.; Yuan, H.; Miki, T.; Sato, S.; Horimoto, N.; Shimizu, T.; Seino, S.; Inagaki, N. Protective role of ATP-sensitive potassium channels in hypoxia-induced generalized seizure. Science, 2001, 292(5521), 1543-1546. DOI: http://dx.doi.org/10. 1126/science.1059829
115. Bantel, C.; Maze, M.; Trapp, S. Noble gas xenon is a novel adenosine triphosphate-sensitive potassium channel opener. Anesthesiology, 2010, 112(3), 623-630. DOI: http://dx.doi.org/ 10.1097/ALN.0b013e3181cf894a
116. Franks, N. P.; Dickinson, R.; de Sousa, S. L.; Hall, A. C.; Lieb, W. R. How does xenon produce anaesthesia? Nature, 1998, 396(6709), 324. DOI: http://dx.doi.org/10.1016/0140-6736(90)91872-8
117. Natale, G.; Cattano, D.; Abramo, A.; Forfori, F.; Fulceri, F.; Fornai, F.; Paparelli, A.; Giunta, F. Morphological evidence that xenon neuroprotects against N-methyl-DL-aspartic acid-induced damage in the rat arcuate nucleus: a time-dependent study. Ann. N Acad. Sci., 2006, 1074, 650-658. DOI: http://dx.doi.org/10.1196/ annals.1369.063
118. Dickinson, R.; Peterson, B. K.; Banks, P.; Simillis, C.; Martin, J. C.; Valenzuela, C. A.; Maze, M.; Franks, N. P. Competitive inhibition at the glycine site of the N-methyl-D-aspartate receptor by the anesthetics xenon and isoflurane: evidence from molecular modeling and electrophysiology. Anesthesiology, 2007, 107(5), 756-767. DOI: http://dx.doi.org/10.1097/01.anes.0000287061.77674.71
119. Petzelt, C. P.; Kodirov, S.; Taschenberger, G.; Kox, W. J. Participation of the Ca(2+)-calmodulin-activated Kinase II in the control of metaphase-anaphase transition in human cells. Cell. Biol. Int., 2001, 25(5), 403-409. PMID: 11401327
120. Dinse, A.; Fohr, K. J.; Georgieff, M.; Beyer, C.; Bulling, A.; Weigt, H. U. Xenon reduces glutamate-, AMPA-, and kainateinduced membrane currents in cortical neurones. Br. J. Anaesth., 2005, 94(4), 479-485. DOI: http://dx.doi.org/10.1093/bja/aei080
121. Green, D. R.; Reed, J. C. Mitochondria and apoptosis. Science, 1998, 281(5381), 1309-1312. DOI: http://dx.doi.org/10.1126/ science.281.5381.1309
122. Shindler, K. S.; Latham, C. B.; Roth, K. A. Bax deficiency prevents the increased cell death of immature neurons in bcl-x-deficient mice. J. Neurosci., 1997, 17(9), 3112-3119. PMID: 9096145
123. Martin, J. L.; Ma, D.; Hossain, M.; Xu, J.; Sanders, R. D.; Franks, N. P.; Maze, M. Asynchronous administration of xenon and hypothermia significantly reduces brain infarction in the neonatal rat. Br. J. Anaesth., 2007, 98(2), 236-240. DOI: http://dx.doi.org/ 10.1093/bja/ael340
124. Gruss, M.; Bushell, T. J.; Bright, D. P.; Lieb, W. R.; Mathie, A.; Franks, N. P. Two-pore-domain K+ channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane. Mol. Pharmacol., 2004, 65(2), 443-452. DOI: http://dx.doi.org/10.1124/ mol.65.2.443
125. Weber, N. C.; Toma, O.; Wolter, J. I.; Obal, D.; Mullenheim, J.; Preckel, B.; Schlack, W. The noble gas xenon induces pharmacological preconditioning in the rat heart in vivo via induction of PKC-epsilon and p38 MAPK. Br. J. Pharmacol., 2005, 144(1), 123-132. DOI: http://dx.doi.org/10.1038/sj.bjp. 0706063
126. Wilson, B. E.; Mochon, E.; Boxer, L. M. Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol. Cell. Biol., 1996, 16(10), 5546-5556. PMCID: PMC231554
127. Wilhelm, S.; Ma, D.; Maze, M.; Franks, N. P. Effects of xenon on in vitro and in vivo models of neuronal injury. Anesthesiology, 2002, 96(6), 1485-1491. DOI: http://dx.doi.org/10.1097/00000542- 200206000-00031
128. Tymianski, M.; Sattler, R.; Zabramski, J. M.; Spetzler, R. F. Characterization of neuroprotection from excitotoxicity by moderate and profound hypothermia in cultured cortical neurons unmasks a temperature-insensitive component of glutamate neurotoxicity. J. Cereb. Blood Flow Metab., 1998, 18(8), 848-867. DOI: http://dx.doi.org/10.1097/00004647-199808000-00005
129. Bossenmeyer-Pourie, C.; Koziel, V.; Daval, J. L. Effects of hypothermia on hypoxia-induced apoptosis in cultured neurons from developing rat forebrain: comparison with preconditioning. Pediatr. Res., 2000, 47(3), 385-391. DOI: http://dx.doi.org/10. 1203/00006450-200003000-00017
130. Xu, L.; Yenari, M. A.; Steinberg, G. K.; Giffard, R. G. Mild hypothermia reduces apoptosis of mouse neurons in vitro early in the cascade. J. Cereb. Blood Flow Metab., 2002, 22(1), 21-28. DOI: http://dx.doi.org/10.1097/00004647-200201000-00003
131. Ma, D.; Hossain, M.; Chow, A.; Arshad, M.; Battson, R. M.; Sanders, R. D.; Mehmet, H.; Edwards, A. D.; Franks, N. P.; Maze, M. Xenon and hypothermia combine to provide neuroprotection from neonatal asphyxia. Ann. Neurol., 2005, 58(2), 182-193. DOI: http://dx.doi.org/10.1002/ana.20547
132. Sheng, S. P.; Lei, B.; James, M. L.; Lascola, C. D.; Venkatraman, T. N.; Jung, J. Y.; Maze, M.; Franks, N. P.; Pearlstein, R. D.; Sheng, H.; Warner, D. S. Xenon neuroprotection in experimental stroke: interactions with hypothermia and intracerebral hemorrhage. Anesthesiology, 2012, 117(6), 1262-1275. DOI: http://dx.doi.org/ 10.1097/ALN.0b013e3182746b81
133. David, H. N.; Haelewyn, B.; Risso, J. J.; Colloc'h, N.; Abraini, J. H. Xenon is an inhibitor of tissue-plasminogen activator: adverse and beneficial effects in a rat model of thromboembolic stroke. J. Cereb. Blood Flow Metab., 2010, 30(4), 718-728. DOI: http://dx.doi.org/10.1038/jcbfm.2009.275
134. Iseri, L. T.; French, J. H. Magnesium: nature's physiologic calcium blocker. Am. Heart J., 1984, 108(1), 188-193. DOI: http://dx.doi. org/10.1016/0002-8703(84)90572-6
135. Altura, B. T.; Altura, B. M. Interactions of Mg and K on cerebral vessels--aspects in view of stroke. Review of present status and new findings. Magnesium, 1984, 3(4-6), 195-211. PMID: 6399342
136. Huang, Q. F.; Gebrewold, A.; Altura, B. T.; Altura, B. M. Mg2+ protects against PCP-induced cerebrovasospasms and vascular damage in rat brain. Magnes. Trace Elem., 1990, 9(1), 44-46. PMID: 2158788
137. Ghribi, O.; Callebert, J.; Verrecchia, C.; Plotkine, M.; Boulu, R. G. Blockers of NMDA-operated channels decrease glutamate and aspartate extracellular accumulation in striatum during forebrain ischaemia in rats. Fundam. Clin. Pharmacol., 1995, 9(2), 141-146. DOI: http://dx.doi.org/10.1111/j.1472-8206.1995.tb00273.x
138. Hall, E. D.; McCall, J. M.; Means, E. D. Therapeutic potential of the lazaroids (21-aminosteroids) in acute central nervous system trauma, ischemia and subarachnoid hemorrhage. Adv. Pharmacol., 1994, 28, 221-268. DOI: http://dx.doi.org/10.1016/S1054-3589(08) 60497-4
139. Tsuda, T.; Kogure, K.; Nishioka, K.; Watanabe, T. Mg2+ administered up to twenty-four hours following reperfusion prevents ischemic damage of the Ca1 neurons in the rat hippocampus. Neuroscience, 1991, 44(2), 335-341. DOI: http://dx.doi.org/10. 1016/0306-4522(91)90058-V
140. Sena, E.; Wheble, P.; Sandercock, P.; Macleod, M. Systematic review and meta-analysis of the efficacy of tirilazad in experimental stroke. Stroke, 2007, 38(2), 388-394. DOI: http://dx.doi.org/10. 1161/01.STR.0000254462.75851.22
141. McIntosh, T. K.; Vink, R.; Yamakami, I.; Faden, A. I. Magnesium protects against neurological deficit after brain injury. Brain Res., 1989, 482(2), 252-260. DOI: http://dx.doi.org/10.1016/0006-8993 (89)91188-8
142. Ram, Z.; Sadeh, M.; Shacked, I.; Sahar, A.; Hadani, M. Magnesium sulfate reverses experimental delayed cerebral vasospasm after subarachnoid hemorrhage in rats. Stroke, 1991, 22(7), 922-927. DOI: http://dx.doi.org/10.1161/01.STR.22.7.922
143. Robertson, C. S.; Foltz, R.; Grossman, R. G.; Goodman, J. C. Protection against experimental ischemic spinal cord injury. J. Neurosurg., 1986, 64(4), 633-642. DOI: http://dx.doi.org/10.3171/ jns.1986.64.4.0633
144. Schmid-Elsaesser, R.; Zausinger, S.; Hungerhuber, E.; Baethmann, A.; Reulen, H. J. Neuroprotective effects of combination therapy with tirilazad and magnesium in rats subjected to reversible focal cerebral ischemia. Neurosurgery, 1999, 44(1), 163-171; discussion 171-162. DOI: http://dx.doi.org/10.1097/00006123-199901000- 00101
145. Schmid-Elsaesser, R.; Hungerhuber, E.; Zausinger, S.; Baethmann, A.; Reulen, H. J. Combination drug therapy and mild hypothermia: a promising treatment strategy for reversible, focal cerebral ischemia. Stroke, 1999, 30(9), 1891-1899. DOI: http://dx.doi.org/ 10.1161/01.STR.30.9.1891
146. Scholler, K.; Zausinger, S.; Baethmann, A.; Schmid-Elsaesser, R. Neuroprotection in ischemic stroke--combination drug therapy and mild hypothermia in a rat model of permanent focal cerebral ischemia. Brain Res., 2004, 1023(2), 272-278. DOI: http://dx.doi. org/10.1016/j.brainres.2004.01.094
147. Zausinger, S.; Scholler, K.; Plesnila, N.; Schmid-Elsaesser, R. Combination drug therapy and mild hypothermia after transient focal cerebral ischemia in rats. Stroke, 2003, 34(9), 2246-2251. DOI: http://dx.doi.org/10.1161/01.STR.0000083622.65684.21
148. Suzuki, J.; Tanaka, S.; Yoshimoto, T. Recirculation in the acute period of cerebral infarction: brain swelling and its suppression using mannitol. Surg. Neurol., 1980, 14(6), 467-472. PMID: 6784261
149. Little, J. R. Modification of acute focal ischemia by treatment with mannitol. Stroke, 1978, 9(1), 4-9. DOI: http://dx.doi.org/10.1161/ 01.STR.9.1.4
150. Little, J. R. Treatment of acute focal cerebral ischemia with intermittent, low dose mannitol. Neurosurgery, 1979, 5(6), 687- 691. DOI: http://dx.doi.org/10.1227/00006123-197912000-00007
151. Kagawa, S.; Koshu, K.; Yoshimoto, T.; Suzuki, J. The protective effect of mannitol and perfluorochemicals on hemorrhagic infarction: an experimental study. Surg. Neurol., 1982, 17(1), 66-70. DOI: http://dx.doi.org/10.1016/0090-3019(82)90048-9
152. Burke, A. M.; Quest, D. O.; Chien, S.; Cerri, C. The effects of mannitol on blood viscosity. J. Neurosurg., 1981, 55(4), 550-553. DOI: http://dx.doi.org/10.3171/jns.1981.55.4.0550
153. Andrews, R. J.; Bringas, J. R.; Muto, R. P. Effects of mannitol on cerebral blood flow, blood pressure, blood viscosity, hematocrit, sodium, and potassium. Surg. Neurol., 1993, 39(3), 218-222. DOI: http://dx.doi.org/10.1016/0090-3019(93)90186-5
154. Meyer, F. B.; Anderson, R. E.; Sundt, T. M., Jr.; Yaksh, T. L. Treatment of experimental focal cerebral ischemia with mannitol. Assessment by intracellular brain pH, cortical blood flow, and electroencephalography. J. Neurosurg., 1987, 66(1), 109-115. DOI: http://dx.doi.org/10.3171/jns.1987.66.1.0109
155. Bell, B. A.; Smith, M. A.; Kean, D. M.; McGhee, C. N.; MacDonald, H. L.; Miller, J. D.; Barnett, G. H.; Tocher, J. L.; Douglas, R. H.; Best, J. J. Brain water measured by magnetic resonance imaging. Correlation with direct estimation and changes after mannitol and dexamethasone. Lancet, 1987, 1(8524), 66-69. DOI: http://dx.doi.org/10.1016/S0140-6736(87)91908-8
156. Suzuki J, Y. T. The effect of mannitol in prolongation of permissible occlusion time of cerebral arteries: Clinical data of aneurysm surgery. Neurosurg. Rev., 1979, 1, 13-19. DOI: http://dx.doi.org/10.1007/BF01644042
157. Karibe, H.; Zarow, G. J.; Weinstein, P. R. Use of mild intraischemic hypothermia versus mannitol to reduce infarct size after temporary middle cerebral artery occlusion in rats. J. Neurosurg., 1995, 83(1), 93-98. DOI: http://dx.doi.org/10.3171/jns. 1995.83.1.0093
158. Ogilvy, C. S.; Chu, D.; Kaplan, S. Mild hypothermia, hypertension, and mannitol are protective against infarction during experimental intracranial temporary vessel occlusion. Neurosurgery, 1996, 38(6), 1202-1209; discussion 1209-1210. DOI: http://dx.doi.org/10.1097/ 00006123-199606000-00030
159. Muizelaar, J. P.; Wei, E. P.; Kontos, H. A.; Becker, D. P. Mannitol causes compensatory cerebral vasoconstriction and vasodilation in response to blood viscosity changes. J. Neurosurg., 1983, 59(5), 822-828. DOI: http://dx.doi.org/10.3171/jns.1983.59.5.0822
160. Kotwica, Z.; Persson, L. Effect of mannitol on intracranial pressure in focal cerebral ischemia. An experimental study in a rat. Mater. Med. Pol., 1991, 23(4), 280-284. PMID: 1842234
161. Smith, D. S.; Rehncrona, S.; Siesjo, B. K. Barbiturates as protective agents in brain ischemia and as free radical scavengers in vitro. Acta Physiol. Scand. Suppl., 1980, 492, 129-134. PMID: 6939303
162. Westermaier, T.; Zausinger, S.; Baethmann, A.; Steiger, H. J.; Schmid-Elsaesser, R. No additional neuroprotection provided by barbiturate-induced burst suppression under mild hypothermic conditions in rats subjected to reversible focal ischemia. J. Neurosurg., 2000, 93(5), 835-844. DOI: http://dx.doi.org/10.3171/ jns.2000.93.5.0835
163. Geral, C.; Angelova, A.; Lesieur, S. From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF). Pharmaceutics, 2013, 5(1), 127-167. doi: 10.3390/pharmaceutics5010127
164. Schabitz, W. R.; Schwab, S.; Spranger, M.; Hacke, W. Intraventricular brain-derived neurotrophic factor reduces infarct size after focal cerebral ischemia in rats. J Cereb Blood Flow Metab, 1997, 17(5), 500-506. PMID: 9183287
165. Schabitz, W. R.; Sommer, C.; Zoder, W.; Kiessling, M.; Schwaninger, M.; Schwab, S. Intravenous brain-derived neurotrophic factor reduces infarct size and counterregulates Bax and Bcl-2 expression after temporary focal cerebral ischemia. Stroke, 2000, 31(9), 2212-2217. PMID: 10978054
166. Berger, C.; Schabitz, W. R.; Wolf, M.; Mueller, H.; Sommer, C.; Schwab, S. Hypothermia and brain-derived neurotrophic factor reduce glutamate synergistically in acute stroke. Exp. Neurol., 2004, 185(2), 305-312. DOI: http://dx.doi.org/10.1016/j.expneurol. 2003.10.008
167. Fisher, M.; Meadows, M. E.; Do, T.; Weise, J.; Trubetskoy, V.; Charette, M.; Finklestein, S. P. Delayed treatment with intravenous basic fibroblast growth factor reduces infarct size following permanent focal cerebral ischemia in rats. J Cereb Blood Flow Metab, 1995, 15(6), 953-959. PMID: 7593356
168. Sakane, T.; Pardridge, W. M. Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity. Pharm Res, 1997, 14(8), 1085-1091. PMID: 9279893
169. Silasi, G.; Klahr, A. C.; Hackett, M. J.; Auriat, A. M.; Nichol, H.; Colbourne, F. Prolonged therapeutic hypothermia does not adversely impact neuroplasticity after global ischemia in rats. J Cereb Blood Flow Metab, 2012, 32(8), 1525-1534. doi: 10.1038/ jcbfm.2012.38
170. Olson, L.; Faulkner, S.; Lundstromer, K.; Kerenyi, A.; Kelen, D.; Chandrasekaran, M.; Aden, U.; Olson, L.; Golay, X.; Lagercrantz, H.; Robertson, N. J.; Galter, D. Comparison of three hypothermic target temperatures for the treatment of HI HIHI ischemia: mRNA level responses of eight genes in the piglet brain. Transl Stroke Res, 2013, 4(2), 248-257. doi: 10.1007/s12975-012-0215-4
171. Belayev, L.; Liu, Y.; Zhao, W.; Busto, R.; Ginsberg, M. D. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke, 2001, 32(2), 553-560. DOI: http://dx.doi.org/10.1161/01. STR.32.2.553
172. Ginsberg, M. D.; Hill, M. D.; Palesch, Y. Y.; Ryckborst, K. J.; Tamariz, D. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--I: Physiological responses and safety results. Stroke, 2006, 37(8), 2100-2106. DOI: http://dx.doi.org/10.1161/01.STR.0000231388.72646.05
173. Chen, J.; Fredrickson, V.; Ding, Y.; Cheng, H.; Wang, N.; Ling, F.; Ji, X. Enhanced neuroprotection by local intra-arterial infusion of human albumin solution and local hypothermia. Stroke, 2013, 44(1), 260-262. DOI: http://dx.doi.org/10.1161/STROKEAHA.112. 675462
174. Ivamoto, H. S.; Numoto, M.; Donaghy, R. M. Surgical decompression for cerebral and cerebellar infarcts. Stroke, 1974, 5(3), 365-370. DOI: http://dx.doi.org/10.1161/01.STR.5.3.365
175. Doerfler, A.; Schwab, S.; Hoffmann, T. T.; Engelhorn, T.; Forsting, M. Combination of decompressive craniectomy and mild hypothermia ameliorates infarction volume after permanent focal ischemia in rats. Stroke, 2001, 32(11), 2675-2681. CrossRef DOI: http://dx.doi.org/10.1161/hs1101.098369
176. Jieyong, B.; Zhong, W.; Shiming, Z.; Dai, Z.; Kato, Y.; Kanno, T.; Sano, H. Decompressive craniectomy and mild hypothermia reduces infarction size and counterregulates Bax and Bcl-2 expression after permanent focal ischemia in rats. Neurosurg. Rev., 2006, 29(2), 168-172. DOI: http://dx.doi.org/10.1007/s10143-005- 0010-8
177. Els, T.; Oehm, E.; Voigt, S.; Klisch, J.; Hetzel, A.; Kassubek, J. Safety and therapeutical benefit of hemicraniectomy combined with mild hypothermia in comparison with hemicraniectomy alone in patients with malignant ischemic stroke. Cerebrovasc. Dis., 2006, 21(1-2), 79-85. DOI: http://dx.doi.org/10.1159/000090007
178. Lawrence, M. S.; McLaughlin, J. R.; Sun, G. H.; Ho, D. Y.; McIntosh, L.; Kunis, D. M.; Sapolsky, R. M.; Steinberg, G. K. Herpes simplex viral vectors expressing Bcl-2 are neuroprotective when delivered after a stroke. J. Cereb. Blood Flow Metab., 1997, 17(7), 740-744. DOI: http://dx.doi.org/10.1097/00004647-199707000- 00003
179. Zhao, H.; Yenari, M. A.; Sapolsky, R. M.; Steinberg, G. K. Mild postischemic hypothermia prolongs the time window for gene therapy by inhibiting cytochrome C release. Stroke, 2004, 35(2), 572-577. DOI: http://dx.doi.org/10.1161/01.STR.0000110787. 42083.58
180. Wadia, J. S.; Dowdy, S. F. Protein transduction technology. Curr. Opin. Biotechnol., 2002, 13(1), 52-56. http://dx.doi.org/10.1016/ S0958-1669(02)00284-7
181. Beerens, A. M.; Al Hadithy, A. F.; Rots, M. G.; Haisma, H. J. Protein transduction domains and their utility in gene therapy. Curr. Gene Ther., 2003, 3(5), 486-494. DOI: http://dx.doi.org/10. 2174/1566523034578258
182. Denicourt, C.; Dowdy, S. F. Protein transduction technology offers novel therapeutic approach for brain ischemia. Trends Pharmacol. Sci., 2003, 24(5), 216-218. DOI: http://dx.doi.org/10.1016/S0165- 6147(03)00074-9
183. Asoh, S.; Ohsawa, I.; Mori, T.; Katsura, K.; Hiraide, T.; Katayama, Y.; Kimura, M.; Ozaki, D.; Yamagata, K.; Ohta, S. Protection against ischemic brain injury by protein therapeutics. Proc. Natl. Acad. Sci. U. S. A., 2002, 99(26), 17107-17112. DOI: http://dx.doi. org/10.1073/pnas.262460299
184. Katsura, K.; Takahashi, K.; Asoh, S.; Watanabe, M.; Sakurazawa, M.; Ohsawa, I.; Mori, T.; Igarashi, H.; Ohkubo, S.; Katayama, Y.; Ohta, S. Combination therapy with transductive anti-death FNK protein and FK506 ameliorates brain damage with focal transient ischemia in rat. J. Neurochem., 2008, 106(1), 258-270. DOI: http://dx.doi.org/10.1111/j.1471-4159.2008.05360.x
185. Sakurazawa, M.; Katsura, K.; Saito, M.; Asoh, S.; Ohta, S.; Katayama, Y. Mild hypothermia enhanced the protective effect of protein therapy with transductive anti-death FNK protein using a rat focal transient cerebral ischemia model. Brain. Res., 2012, 1430, 86-92. DOI: http://dx.doi.org/10.1016/j.brainres.2011.10.041
186. Vannucci, R. C.; Perlman, J. M. Interventions for perinatal HIischemic encephalopathy. Pediatrics, 1997, 100(6), 1004-1014.
187. Levene, M. I.; Sands, C.; Grindulis, H.; Moore, J. R. Comparison of two methods of predicting outcome in perinatal asphyxia. Lancet, 1986, 1(8472), 67-69. PMID: 2867316
188. Hobbs, C.; Thoresen, M.; Tucker, A.; Aquilina, K.; Chakkarapani, E.; Dingley, J. Xenon and hypothermia combine additively, offering long-term functional and histopathologic neuroprotection after neonatal hypoxia/ischemia. Stroke, 2008, 39(4), 1307-1313. doi: 10.1161/STROKEAHA.107.499822.
189. Ikonomidou, C.; Mosinger, J. L.; Olney, J. W. Hypothermia enhances protective effect of MK-801 against hypoxic/ischemic brain damage in infant rats. Brain Res, 1989, 487(1), 184-187. PMID: 2546648
190. Alkan, T.; Kahveci, N.; Buyukuysal, L.; Korfali, E.; Ozluk, K. Neuroprotective effects of MK 801 and hypothermia used alone and in combination in hypoxic-ischemic brain injury in neonatal rats. Arch Physiol Biochem, 2001, 109(2), 135-144. PMID: 11780774
191. Xu, S. Y.; Pan, S. Y. The failure of animal models of neuroprotection in acute ischemic stroke to translate to clinical efficacy. Med. Sci. Monit. Basic Res., 2013, 19, 37-45. PMID: 23353570
192. Fisher, M.; Albers, G. W.; Donnan, G. A.; Furlan, A. J.; Grotta, J. C.; Kidwell, C. S.; Sacco, R. L.; Wechsler, L. R.; Stroke Therapy Academic Industry Roundtable, I. V. Enhancing the development and approval of acute stroke therapies: Stroke Therapy Academic Industry roundtable. Stroke, 2005, 36(8), 1808-1813.DOI: http://dx. doi.org/10.1161/01.STR.0000173403.60553.27s